Literature DB >> 19016024

Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?

Roy F A Vliegen1, Regina G Beets-Tan, Bart Vanhauten, Ann Driessen, Michel Oellers, Alfons G Kessels, Ann Arens, Geerard L Beets, Jeroen Buijsen, Angela van Baardwijk, Dirk de Ruysscher, Guido Lammering.   

Abstract

BACKGROUND AND
PURPOSE: More effective preoperative treatment in locally advanced rectal cancer gives rise to a more individualized, conservative surgical treatment strategy. This, however, requires accurate information on tumor response after chemoradiation (CRT). So far, MRI and CT have failed to provide such information. Therefore, the value of a combined FDG-PET/CT in predicting tumor clearance of the mesorectal fascia (MRF) was determined. PATIENTS AND METHODS: 20 rectal cancer patients with MRF tumor invasion underwent preoperative PET/CT before and on average 6.3 weeks after CRT. The SUV(max)(maximal standard uptake value) on sequential PET/CT and the shortest distance between the outlined tumor volume and the MRF measured by using autocontouring software on post-CRT PET/CT were registered. The surgical specimen was evaluated for tumor clearance of the MRF and the tumor regression grade (TRG).
RESULTS: The TRG significantly corresponded with the SUV(max)changes induced by CRT (p = 0.025), and showed a trend with the post-CRT SUV(max)(TRG 1-2 vs. TRG 3-5: SUV(max)= 3.0 vs. 5.0; p = 0.06). However, the pathologically verified tumor clearance of the MRF was not correlated with any of the tested SUV parameters nor with the shortest distance between the residual tumor and the MRF.
CONCLUSION: Post-CRT PET/CT is not a useful tool for evaluating anatomic tumor changes and, therefore, not accurate in predicting tumor clearance of the MRF. However, it might be a useful tool in predicting pathologic tumor response after CRT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016024     DOI: 10.1007/s00066-008-1858-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  17 in total

1.  Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation.

Authors:  Shane Hopkins; Marwan Fakih; Gary Y Yang
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

2.  ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.

Authors:  Felipe A Calvo; Claudio V Sole; Dolores de la Mata; Luis Cabezón; Marina Gómez-Espí; Emilio Alvarez; Paz Madariaga; José L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-23       Impact factor: 9.236

3.  Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging.

Authors:  I Song; S H Kim; S J Lee; J Y Choi; M J Kim; H Rhim
Journal:  Br J Radiol       Date:  2011-02-22       Impact factor: 3.039

Review 4.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

5.  [Rectal cancer - local staging and imaging under neoadjuvant therapy].

Authors:  M Karpitschka
Journal:  Radiologe       Date:  2012-06       Impact factor: 0.635

6.  Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET.

Authors:  Mathieu Hatt; Ruud van Stiphout; Adrien le Pogam; Guido Lammering; Dimitris Visvikis; Philippe Lambin
Journal:  Acta Oncol       Date:  2012-08-08       Impact factor: 4.089

Review 7.  Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?

Authors:  Claus Rödel; Dirk Arnold; Heinz Becker; Rainer Fietkau; Michael Ghadimi; Ullrich Graeven; Clemens Hess; Ralf Hofheinz; Werner Hohenberger; Stefan Post; Rudolf Raab; Rolf Sauer; Frederick Wenz; Torsten Liersch
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

8.  Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy?

Authors:  Li-Jen Kuo; Jeng-Fong Chiou; Cheng-Jeng Tai; Chun-Chao Chang; Ching-Huei Kung; Sey-En Lin; Chin-Sheng Hung; Weu Wang; Ka-Wai Tam; Hung-Chia Lee; Hung-Hua Liang; Yu-Jia Chang; Po-Li Wei
Journal:  Int J Colorectal Dis       Date:  2011-11-15       Impact factor: 2.571

9.  High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Authors:  Hendrik Andreas Wolff; Jochen Gaedcke; Klaus Jung; Robert Michael Hermann; Hilka Rothe; Markus Schirmer; Torsten Liersch; Markus Karl Alfred Herrmann; Steffen Hennies; Margret Rave-Fränk; Clemens Friedrich Hess; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 10.  [The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer].

Authors:  Claus Rödel; Rolf Sauer; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.